Stocktoria
Enovis CORP ENOV
Enovis CORP (ENOV) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 0.02% (safety: no dividend). FY2025 revenue was $2.2B at a -52.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.33 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.159 |
| Retained earnings / assets | -0.383 |
| EBIT / assets | -0.293 |
| Equity / liabilities | 0.637 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENOV | Enovis CORP | 4/9 | -1.51 | — | +6.7% |
| MSA | MSA Safety Inc | 6/9 | 5.65 | 23.6 | +3.7% |
| AVNS | AVANOS MEDICAL, INC. | 5/9 | 1.17 | — | +1.9% |
| CDRE | Cadre Holdings, Inc. | 6/9 | 3.7 | 27.2 | +7.5% |
| ALGN | ALIGN TECHNOLOGY INC | 6/9 | 4.56 | 31.1 | +0.9% |
| INGN | Inogen Inc | 4/9 | 2.26 | — | +3.9% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | 4/9 | -2.1 | — | +27.1% |
About Enovis CORP
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
FAQ
Is ENOV financially healthy?
Enovis CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ENOV pay a dividend, and is it safe?
Yes. Enovis CORP pays a dividend yielding about 0.02% with a None payout ratio, rated “no dividend” for safety.
How profitable is ENOV?
In FY2025, Enovis CORP had a net margin of -52.7% and a return on equity of -79.4%.
Is ENOV overvalued or undervalued?
Enovis CORP trades at about 17.6× trailing earnings — below its 10-year norm (10-year range 25.8×–522.5×, median 56.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ENOV?
The average Wall-Street price target for Enovis CORP is $42.30, about 71.3% above the recent price, from 10 analysts (consensus: strong buy).
Is ENOV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Enovis CORP: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a dividend yield of 0.02%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.